Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 17/20 | 0.53 |
| ▸ | PARP2 | Q9UGN5 | 5/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6841114 | 0.85 | PARP1 (0.48) | PARP1PARP2 | |
| SCHEMBL6841873 | 0.77 | PARP1 (0.62) | PARP1PARP2 | |
| SCHEMBL1388106 | 0.76 | DRD2 (0.71) | KDM4EALDH1A1HSD17B10 | |
| SCHEMBL25022851 | 0.73 | PARP1 (0.63) | PARP1PARP2 | |
| SCHEMBL7200439 | 0.73 | AURKA (0.57) | PARP1 | |
| SCHEMBL23581692 | 0.72 | PARP1 (0.66) | PARP1 | |
| SCHEMBL6841122 | 0.72 | PARP1 (0.61) | PARP1PARP2 | |
| SCHEMBL7479562 | 0.71 | PARP1 (0.56) | PARP1KDM4E | |
| SCHEMBL29412049 | 0.70 | PARP1 (0.60) | PARP1 | |
| SCHEMBL12385320 | 0.70 | PARP1 (0.62) | PARP1PARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040034078-A1 | Benzimidazole inhibitors of poly(ADP-ribosyl) polymerase | AGOURON PHARMACEUTICALS, INC. | 2004-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034078-A1 | Benzimidazole inhibitors of poly(ADP-ribosyl) polymerase | PARP1, PARP11, PARP2 | PARP1 1/4885PARP2 3/4885KDM4E 2460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.